In-detail Table of Contents of Duchenne Muscular Dystrophy Pipeline Market
Companies Involved in Therapeutics Development Acceleron Pharma, Inc., Anagenesis Biotechnology, Asklepios BioPharmaceutical, Inc., Bamboo Therapeutics, Inc., BioMarin Pharmaceutical Inc., Bristol-Myers Squibb Company, Capricor Therapeutics, Inc., Catabasis Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Debiopharm International S.A., Editas Medicine, Inc., Eli Lilly and Company, EryDel SPA, FibroGen, Inc., Galapagos NV, Genethon, GTx, Inc., Idera Pharmaceuticals, Inc., Italfarmaco S.p.A., La Jolla Pharmaceutical Company, Marathon Pharmaceuticals, LLC, Marina Biotech, Inc., Merck KGaA, Milo Biotechnology LLC, MyoTherix Inc., NicOx S.A., Nippon Shinyaku Co., Ltd., nLife Therapeutics, S.L., Nobelpharma Co., Ltd., Pfizer Inc., Prothelia, Inc., PTC Therapeutics, Inc., RASRx, LLC, ReveraGen BioPharma, Inc., Sanofi, Santhera Pharmaceuticals Holding AG, Sarepta Therapeutics, Inc., Summit Therapeutics Plc, Taiho Pharmaceutical Co., Ltd., WAVE Life Sciences Ltd. and Zambon Company S.p.A.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Enquire before buying this research at http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=521087 .
Scope for this research:
· The report provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy
· The report reviews pipeline therapeutics for Duchenne Muscular Dystrophy by companies and universities/research institutes based on information derived from company and industry-specific sources
· The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
· The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
· The report reviews key players involved Duchenne Muscular Dystrophy therapeutics and enlists all their major and minor projects
· The report assesses Duchenne Muscular Dystrophy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
· The report summarizes all the dormant and discontinued pipeline projects
· The report reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy
The report provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects.
Complete research report at http://www.rnrmarketresearch.com/duchenne-muscular-dystrophy-pipeline-review-h1-2016-market-report.html .
List of Figures
· Number of Products under Development for Duchenne Muscular Dystrophy, H1 2016
· Number of Products under Development for Duchenne Muscular Dystrophy - Comparative Analysis, H1 2016
· Number of Products under Development by Companies, H1 2016
· Number of Products under Investigation by Universities/Institutes, H1 2016
· Comparative Analysis by Late Stage Development, H1 2016
· Comparative Analysis by Clinical Stage Development, H1 2016
· Comparative Analysis by Early Stage Products, H1 2016
· Assessment by Monotherapy Products, H1 2016
· Number of Products by Top 10 Targets, H1 2016
· Number of Products by Stage and Top 10 Targets, H1 2016
· Number of Products by Top 10 Mechanism of Actions, H1 2016
· Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
· Number of Products by Routes of Administration, H1 2016
· Number of Products by Stage and Routes of Administration, H1 2016
· Number of Products by Top 10 Molecule Types, H1 2016
· Number of Products by Stage and Molecule Types, H1 2016